ABSTRACT Isoniazid (INH) is the cornerstone of tuberculosis (TB) chemotherapy, used for both treatment and prophylaxis of TB. The antimycobacterial activity of INH was discovered in 1952, and almost as soon as its activity was published, the first INH-resistant Mycobacterium tuberculosis strains were reported. INH and its structural analog and second-line anti-TB drug ethionamide (ETH) are pro-drugs. INH is activated by the catalaseperoxidase KatG, while ETH is activated by the monooxygenase EthA. The resulting active species reacts with NAD + to form an INH-NAD or ETH-NAD adduct, which inhibits the enoyl ACP reductase InhA, leading to mycolic acid biosynthesis inhibition and mycobacterial cell death. The major mechanism of INH resistance is mutation in katG, encoding the activator of INH. One specific KatG variant, S315T, is found in 94% of INH-resistant clinical isolates. The second mechanism of INH resistance is a mutation in the promoter region of inhA (c-15t), which results in inhA overexpression and leads to titration of the drug. Mutations in the inhA open reading frame and promoter region are also the major mechanism of resistance to ETH, found more often in ETH-resistant clinical isolates than mutations in the activator of ETH. Other mechanisms of resistance to INH and ETH include expression changes of the drugs' activators, redox alteration, drug inactivation, and efflux pump activation. In this article, we describe each known mechanism of resistance to INH and ETH and its importance in M. tuberculosis clinical isolates.
THE EMERGENCE OF DRUG RESISTANCE
Tuberculosis (TB) chemotherapy started in the 1930s with the discovery by Domagk and colleagues of the anti-TB activity of sulfonamides. Since these compounds were very toxic and highly insoluble, analogs were synthesized, leading to the discovery of Tibione (thiacetazone, Fig. 1 ), a highly effective thiosemicarbazone against Mycobacterium tuberculosis (1, 2) . In parallel, the natural product streptomycin (SM), discovered by Schatz and Waksman, showed activity against M. tuberculosis (3) and was used successfully to treat TB patients. Two new anti-TB drugs were discovered soon after: paraaminosalicylic acid (PAS) in 1946 (4) and isonicotinic acid hydrazine (isoniazid, INH) in 1952 (5, 6) . Each drug had activity against M. tuberculosis; however, drug-resistant mutants emerged rapidly during clinical trials (7) (8) (9) . To prevent drug resistance, in 1959, SM, PAS, and INH were combined to form the first successful multidrug, biphasic chemotherapy for TB (10) . This combination treatment was so impressive that Selman Waksman wrote, "the ancient foe of man, known as consumption, the great white plague, tuberculosis, or by whatever other name, is on the way to being reduced to a minor ailment of man. The future appears bright indeed, and the complete eradication of the disease is in sight" (185, p. 217) . Nevertheless, the treatment was long and expensive, and patients often dropped out prior to completing chemotherapy. In 1984, a new short-course treatment was established that showed improved efficacy and patient compliance; the drug regimen consisted of two months on INH, rifampicin (RIF), pyrazinamide (PZA), and ethambutol, followed by four months on INH and RIF only.
Despite this successful chemotherapy, the rate of multidrug-resistant (MDR) M. tuberculosis strains, defined as strains resistant to INH and RIF, started to increase as early as 1985. Nowadays, the World Health Organization (WHO) estimates that 3.7% of new TB cases and 20% of previously treated TB cases are caused by MDR-TB (11). The highest incidence of MDR-TB (up to 76%) is found in Russia and the former Soviet republics. Extensively drug-resistant (XDR)-TB, defined as TB strains resistant to INH, RIF, fluoroquinolones, and one second-line injectable drug, is found in up to 9% of MDR-TB cases and has been reported in at least 84 countries so far. Furthermore, strains of M. tuberculosis that are resistant to up to 10 TB drugs, referred to as totally drug-resistant (TDR-TB), have been isolated in Europe, Africa, India, and Iran (12). One factor in the emergence and rapid spread of drug resistance is the paucity of rapid diagnostics. While new tools are available to quickly assess drug resistance, these methods are based on known drug resistance mechanisms. Understanding all these mechanisms is key to improving diagnosis and eradicating drug-resistant M. tuberculosis. In this article, we will discuss the mechanisms that M. tuberculosis developed to become resistant to the first-line anti-TB drug INH and its analog, the second-line anti-TB drug ethionamide (ETH).
MODE OF ACTION OF INH AND ETH INH
The antimycobacterial activity of INH was published and commercialized simultaneously by three independent pharmaceutical companies: Bayer (Neoteben) (13) , Hoffman-La Roche (Rimifon) (6) , and Squibb Institute for Medical Research (Nydrazid) (5) . INH had been first synthesized 40 years earlier and reported in a doctoral thesis; therefore, none of the pharmaceutical companies could patent the discovery. Fox (6) described the discovery of INH as an attempt to combine the anti-TB activity of nicotinamide, which had been found to arrest M. tuberculosis growth in guinea pigs (14) , and thiosemicarbazones. By replacing the benzene ring of Tibione by the pyridine ring found in nicotinamide ( Fig. 1) , meta-and para-pyridylaldehyde thiosemicarbazones were synthesized. All the intermediates in the synthesis of these pyridine thiosemicarbazones were tested for activity against TB, and among them, one intermediate, INH, had antimycobacterial activity far superior to any compound at the time (6) . Notably, another analog synthesized, Marsilid (1-isonicotinoyl-2-isopropylhydrazine) ( Fig. 1) , also showed good anti-TB activity. The use of Marsilid as a TB drug was soon discontinued because it induced euphoria in TB patients. However, Marsilid did go on to become the first antidepressant. Interestingly, the earlier synthetic compounds active to some degree against M. tuberculosis share a similar chemical skeleton (Fig. 1) , although their modes of action are different. The mechanism of action of INH has been the subject of intensive research and controversies since its discovery in 1952. From 1953 to 1980, multiple modes of action for INH were proposed: INH was thought to interfere with cell division (15) , pyridoxal-dependent metabolic pathway(s) (16) , lipid biosynthesis (17) , fatty acid biosynthesis (18) , nucleic acid biosynthesis (19) , glycerol conversion to hexose phosphate (20) , NAD + biosynthesis (21) , and NADH dehydrogenase activity (22) (23) . A major breakthrough in understanding the mechanism of action of INH came with the study by Winder and Collins (186) in which they showed that INH inhibited synthesis of mycolic acids, long-chain α-alkyl β-hydroxy fatty acids that are a crucial component of the mycobacterial cell wall. The effect of INH on mycolic acids has been subsequently confirmed by numerous researchers. Among them, Takayama and coworkers were the first to demonstrate that inhibition of mycolic acid biosynthesis by INH correlated with cell death (24) , accumulation of long-chain fatty acids (25) , and inhibition of C24 and C26 monounsaturated fatty acid biosyntheses (26) . Takayama and colleagues concluded that the mode of action of INH involved a desaturase required for the biosynthesis of these unsaturated fatty acids (26) .
INH, like other TB drugs (ETH, PZA, isoxyl, thiacetazone) is a pro-drug. The catalase peroxidase KatG (encoded by Rv1908c) activates INH to form a hypothetical isonicotinoyl anion or radical (27) (28) (29) (30) . This entity reacts with NAD + to yield an INH-NAD adduct, which binds to the active site of the NADH-dependent enoyl-ACP reductase InhA (Rv1484) (Fig. 2) (31) . This enzyme reduces monounsaturated acyl-ACP to acyl-ACP (32, 33) and is part of the fatty acid synthase type II (FASII) (34) . FASII elongates fatty acids up to 56 carbons long where they are derivatized and coupled to a C24-C26 fatty acid generated by FASI to form mycolic acids. The INH-NAD adduct binds to and inhibits InhA (28, 35, 36) , leading to disruption of mycolic acid biosynthesis and cell death (37, 38) .
ETH
2-Ethylthioisonicotinamide, ETH (Fig. 1) , is a structural analog of INH. ETH was first synthesized in 1956 by a French team trying to improve on the antimycobacterial properties of thioisonicotinamide (39) . Grumbach and coworkers found that ETH was more active than SM but less so than INH against M. tuberculosis. However, ETH was also active against INH-, PAS-, and SMresistant M. tuberculosis strains. ETH was shown to be efficacious in combination with PZA and with or without INH in a clinical trial to treat TB patients infected with INH-and SM-resistant strains (40, 41) . Nowadays, ETH is a second-line drug, mostly used to treat MDR-TB cases in South Africa.
Similar to INH (42, 43) , M. tuberculosis treated with ETH loses its acid fastness (39) and its ability to synthesize mycolic acids (44) . ETH is also a prodrug, activated by the NADPH-specific flavin adenine dinucleotide-containing monooxygenase EthA (also called EtaA, encoded by Rv3854c) (45) (46) (47) (48) . Once activated, the mode of action of ETH is very similar to INH (Fig. 2) . The active form of ETH reacts with NAD + to yield an ETH-NAD adduct (49) , which inhibits InhA, leading to mycolic acid biosynthesis inhibition. Interestingly, while KatG only activates INH, EthA activates two other second-line anti-TB drugs: Tibione (thiacetazone) and isoxyl (46, 50) .
MECHANISMS OF RESISTANCE TO INH AND ETH
Drug resistance in mycobacteria is due to the acquisition of mutations or efflux pump activation, not due to the acquisition of resistance plasmids or transposons, common resistance mechanisms in other bacterial species. The main mechanisms of resistance to INH and ETH can be divided into two categories. First, prevention of the activation of INH and ETH can be obtained by mutating the activators of the drugs katG and ethA, respectively, or by mutating regulators of their expression. For example, the katG(S315T) mutation is found in up to 94% of INH-resistant M. tuberculosis clinical isolates. Second, the inhibition of InhA by the INH-NAD or ETH-NAD adduct can be overcome by mutations in inhA or its promoter region. Other mechanisms of resistance exist such as drug inactivators, redox alteration, and efflux pumps. We will first describe the mechanisms of coresistance to INH and ETH and then the mechanisms of resistance specific to each drug.
Common Mechanisms of Resistance to INH and ETH
Clinical isolates coresistant to INH and ETH were isolated from TB patients who had received INH but had never been treated with ETH (51) (52) (53) . This conundrum led to the hypothesis that INH and ETH shared a common mechanism of resistance, a hypothesis that could not be tested until a plasmid transformation system was developed for mycobacteria (54, 55) . It would take another three decades to discover that INH and ETH target the same enzyme in M. tuberculosis: the enoyl-ACP reductase InhA (56) . Other mechanisms of coresistance to INH and ETH have been discovered. These mechanisms along with resistance mechanisms due to inhA mutations are listed below.
Alteration of InhA, the target of INH and ETH
The target of INH and ETH was discovered by isolating a Mycobacterium smegmatis mutant coresistant to INH and ETH (56) . A genomic DNA cosmid library of this M. smegmatis mutant and of drug-susceptible Mycobacterium avium, Mycobacterium bovis, M. smegmatis, and M. tuberculosis strains was constructed and transformed into M. smegmatis. A single open reading frame (ORF) was found to be sufficient to confer coresistance to INH and ETH in M. smegmatis and was named inhA. These experiments demonstrated that a single amino acid mutation in inhA(S94A) or overexpression of inhA conferred coresistance to INH and ETH in mycobacteria. To prove that inhA inactivation was sufficient to lead to death in a manner similar to INH action, a temperature-sensitive mutant in inhA was isolated (37) . Heat-inactivation of InhA(V238F) mimicked the effects of INH in M. tuberculosis described by Takayama and colleagues: inhibition of mycolic acid biosynthesis (24) , alteration of the bacterium morphology (57), accumulation of long-chain fatty acids (25) , and cell death (24) , demonstrating that inhibition of InhA alone reproduced the biochemical characteristics of INH treatment of M. tuberculosis. Moreover, the S94A mutation identified in the INH-and ETH-resistant M. smegmatis mutant was transferred into wild-type M. tuberculosis by specialized linkage transduction, and the resulting strain was at least five times more resistant to INH and ETH than wild-type M. tuberculosis (38) . This combined set of data confirms that InhA is the main target and the main mechanism of coresistance to INH and ETH.
The mechanism by which the S94A mutation leads to resistance to INH and ETH has been well studied. InhA is an NADH-dependent enoyl-ACP reductase, and the binding of the enoyl substrate to InhA is not disturbed by the S94A mutation; however, the mutation results in a 5-fold increase in the K M for the InhA cofactor NADH (32) . On the other hand, the ability of the INH-NAD adduct to inhibit InhA(S94A) is markedly reduced, because the IC 50 (38) . Others disputed this conclusion and hypothesized that InhA interacts with FASII enzymes and that this interaction is perturbed by the S94A mutation, resulting in INH resistance (58) . Overexpression of inhA is also a common factor of INH and ETH resistance in clinical isolates. The c-15t base pair change in the inhA regulatory region increases inhA mRNA levels by 20-fold, resulting in the overexpression of InhA. This leads to a titration of INH or ETH and consequently an eight-fold increase in INH and ETH MICs in M. tuberculosis (38) .
Numerous point mutations in inhA and its promoter region have been identified in INH-and ETH-resistant M. tuberculosis clinical isolates (Tables 1 and 2) ; however, no base pair insertions or deletions have been observed. Mutations in the inhA promoter and ORF regions are associated with low-level resistance to INH, even when strains contained mutations in both regions (MIC <1 mg/liter) (59) . The c-15t mutation in the promoter region of inhA is found in up to 35% of INHresistant and 55% of ETH-resistant clinical isolates, but never in INH-or ETH-sensitive strains. This mutation was also overly represented in XDR-TB cases in South Africa. In a study on clinical isolates from the Western Cape Province, South Africa, the c-15t mutation was present in 30% of strains mono-resistant to INH, 48% of MDR-TB, and 85% of XDR-TB (60), suggesting that this mutation could be a marker for XDR-TB. Interestingly, in a survey of the Eastern Cape Province clinical isolates, the c-17t inhA promoter mutation was the predominant genetic modification present in 83% of XDR-TB cases. The combined inhA promoter mutations (at positions -8, -15, and -17) were found in 92% of the XDR-TB cases versus 62% of the MDR-TB cases in the Eastern Cape Province (60) .
inhA is an essential gene; therefore, mutations in the coding region of inhA are rare. About 15 mutations in inhA have been identified in INH-resistant clinical isolates, although two of them were also found in INHsensitive strains (Table 1) . I21T, S94A, and I95P are the only amino acid changes found in both INH-and ETHresistant clinical isolates. The first mutation identified in inhA in M. smegmatis, resulting in the S94A variant, has since been found in INH-resistant M. tuberculosis clinical isolates with no other mutation present in katG or the fabG-inhA intergenic region (59, 61) . This confirms that the S94A mutation is sufficient to confer INH and ETH resistance in M. tuberculosis clinical isolates.
While mutations in the inhA promoter region can represent up to 35% of the INH-resistant cases, and mutations in the inhA gene are rare in INH-resistant clinical isolates, this is the predominant region where mutations are found in ETH-resistant clinical isolates. In one study (62) , 62% of the ETH-resistant clinical isolates had mutations in inhA (gene and/or promoter region), while 47% had mutations in ethA. The inhA promoter mutation c-15t was therefore proposed as a marker for ETH resistance (63) .
Alteration of redox potential
M. smegmatis and M. bovis BCG mutants coresistant to INH and ETH were isolated in in vitro experiments from nonmutagenized independent cultures. The mutants had mutations in ndh (Rv1854c), a gene encoding a type II NADH dehydrogenase, which oxidizes NADH into NAD + . In M. smegmatis, the ndh mutants contained single base pair changes resulting in amino acid changes and a pleitropic phenotype: INH resistance, ETH resistance, temperature sensitivity, and for some mutants, Ser/Gly auxotrophy (64, 65) . In M. bovis BCG, the mutants had either single base pair changes or insertions (65) . The ndh mutants lost up to 95% of their Ndh activity compared to wild type and had higher levels of NADH, while their NAD + levels were similar to wild type. An increase in NADH concentration was shown to prevent the binding of the INH-NAD adduct to InhA by acting as a competitive inhibitor, leading to INH resistance (65) .
In M. tuberculosis clinical isolates, ndh mutations have been found in both INH-sensitive and INHresistant strains at a very low rate (66) ( Table 1) . However, two studies from Singapore and Brazil identified ndh mutations in 8 to 10% of INH-resistant M. tuberculosis clinical isolates and found no ndh mutations in their INH-sensitive clinical isolate strains (67, 68) . The R13C mutation was found in a strain containing the ASMscience.org/MicrobiolSpectrum (132) g-12a (96) R268H (66, 68) c-72t (131) G313R* (116) g-67a (66) fabG-inhA regulatory region g-66a (133) g-147t (88) iniB atgt-54 ins (92) a-113c (134) t198ins (135) c-54t (132) g-102a (134) a211del (135) c-52t (136) a-92t (69) 222 12bp del (88) g-51a (131) g-67c (137) N88S* (116) t-49g (137) g-47c,a (134, 138) G192* (135) g-48a (135, 139) c-34t (138) H481Q* (116) g-46a* (102, 140) t-24g (141) g-46 del* (66) g-22c (142) iniA c-45t (84) g-17t* (66, 135, 139, 143) P3A (88) t-44a (99) a-16g (84) nt282-286 del (88) t-40c (144) c-15t (66, 88, 135, 139, 140, 143) H481Q* (88, 135) c-39t (66, 135, 139, 140, 144) t-12a (145) R537H (88, 135) t-34c,a (102, 140) a-11t (66) t34 del (102) t-8a*,g,c (66, 88, 140-142) iniC g-32a (140) t-5a (146) t79ins (135) c-30t (66, 144) c-4a (140) a98ins (135) c-20t* (102) A5P (137) W83G (88) c-15t (66, 135, 139, 144) V14L (137) c-12t (66, 135, 139, 140) T21A (66) Rv0340 c-10a,g,t (66, 135, 139, 140) T143* (135) g-9a* (66, 135, 139, 140, 144) inhA ORF G149* (135) g-6a (66, 140, 144) M1L (147) V163I (88, 135) a-4g (140) K8N (148) I16T ( katG (S315T) mutation, so the contribution to the INH resistance of this ndh mutation is uncertain (67) . The ndh (T110A) mutation was only associated with an ahpC mutation resulting in the (T5I) variant (68) . However, in that study, katG was only partially sequenced, and inhA was not (68, 69) , so the INH resistance in that isolate may or may not be due to the ndh(T110A) mutation. The R268H mutation is the only mutation so far to have been identified in two independent studies and only in INH-resistant strains, but it was associated with katG, inhA, or ahpC mutations (66). M. tuberculosis has an additional NADH dehydrogenase named ndhA (Rv0392c). Therefore, mutations in one NADH dehydrogenase such as ndh might not alter the redox balance in M. tuberculosis and might not lead to INH and/or ETH resistance as long as the second NADH dehydrogenase is functional. ndh and ndhA are also present in M. bovis BCG, but M. bovis ndhA codes for a single amino acid change (V241A) relative to M. tuberculosis, which might explain why INH-and ETH-resistant ndh mutants were isolated in that strain. For that reason, ndh mutations might not be a mechanism of resistance to INH and ETH in M. tuberculosis unless both NADH dehydrogenase genes are mutated.
Alteration in mycothiol biosynthesis
Mutations in ndh in INH-resistant M. bovis BCG mutants were isolated in vitro by plating nonmutagenized, independent M. bovis BCG cultures on plates containing both INH and ETH to avoid mutants carrying mutations in the activator of INH or ETH. When the same experiment was repeated in M. tuberculosis H37Rv or the virulent M. bovis Ravenel strain, ndh mutants were not obtained. Instead, all of the INH-and (62) Q246STOP (61) G413D (61) g32 del (154) A248D (154) c1254 del (154) A20 ins (62) Y250STOP (154) g1268 del (154) a65 del (46) cg754 ins (62) c1290 del (61, 154) H22P (62) Q254P (154) gc1322,1323 del (61) Y32D (154) Q254STOP (154) T453I (154) a110 del (61, 154) g768 del (61)* Y461H (62) G43S (61), C (46) S266R (62) R463D (61) T44N (154) Q269STOP (62) a1391 ins (62) D49A (155) Q271STOP (154) Y50C (154) L272P (62) fabG-inhA regulatory region P51L (46) P288R (154) g-17t (61) D55A (61) Q291STOP (154) c-15t (38, 61, 156) D58A (46) R292STOP (154) T61M (62) C294F (154) inhA ORF Y84D (46) F302L (154) I21T (61) 1bp271 del (46) T324 ins (154) S94A (61) cg282-283 del (154) L328M (155) I95P (151) g337 del (154) S329L (62) a338 ins (61) L333R (155) mshA a342 del (154) I338S (61) In M. smegmatis, a 4-to 8-fold increase in INH and ETH resistance was obtained when mshA or mshC was deleted, while deletion of mshB resulted in a strain resistant only to ETH, and deletion of mshD had no effect on INH or ETH resistance (73) (74) . The role of mycothiol deficiency in INH resistance might be species-dependent. So far, we can only conclude that mutations in mshA will result in high-level ETH resistance and at most low-level INH resistance in M. tuberculosis.
In a highly INH-and ETH-resistant clinical isolate, a double mutation in mshA (V171G, A187V) was found (62) . That strain had the katG(S315T) mutation to account for the INH resistance but no other mutation to explain its resistance to ETH. However, the mshA (A187V) mutation is present in wild-type M. tuberculosis Beijing strain. Other mshA mutations have also been found in drug-sensitive mycobacterial strains. The N111S mutation is present in M. tuberculosis Erdman and Haarlem strains (70, 75) , while the M. bovis Ravenel and M. bovis ATCC19210 strains carry a g316a base pair change in mshA, resulting in a G106R amino acid change (71, 75) .
Degradation of the INH-NAD or ETH-NAD adduct
In a recent study, Wang and colleagues suggested that the NADH pyrophosphatase NudC (Rv3199c), an enzyme from the NAD + recycling pathway, could hydrolyze the INH-NAD or ETH-NAD adduct, leading to INH and ETH resistance (76) . M. smegmatis and M. bovis BCG NudC are functional enzymes, while M. tuberculosis H37Rv NudC has a point mutation (Q237P) that renders the enzyme inactive. The authors demonstrated that NudC from M. smegmatis and M. bovis BCG could release the adenosine monophosphate group from the INH-NAD and ETH-NAD adducts and that overexpression of M. smegmatis or M. bovis BCG nudC resulted in at least a 10-fold increased resistance to INH and ETH, while deletion of nudC rendered the strains more sensitive to the drugs. A small portion of M. tuberculosis clinical isolates (2%) were found to have the glutamine residue at position 237, suggesting that in these M. tuberculosis strains, NudC might be capable of hydrolyzing the adducts. However, no transfer of mutation was performed to prove that this mutation is sufficient to confer INH and ETH resistance in M. tuberculosis. The role of nudC in INH and/or ETH resistance in M. tuberculosis clinical isolates remains to be determined.
Mechanisms of Resistance Specific to INH Alterations in KatG, the activator of INH
The first mutants isolated in in vitro cultures that were highly resistant to INH had the characteristic of being catalase-negative and avirulent in guinea pigs (77, 78) . Winder hypothesized that the loss of catalase activity might imply that INH was activated by a catalase to yield some highly reactive species (79 (30, 80) .
In INH-resistant M. tuberculosis clinical isolates, more than 300 mutations in katG have been identified throughout the ORF (Table 3 ). Complete deletion of the gene has been found in clinical isolates, including the first INH-resistant M. tuberculosis mutant identified in the Zhang study (30) ; it has subsequently been identified in other studies (Table 3) . Point mutations causing a single amino acid substitution or premature termination, frameshift mutations after addition or deletion of bases, and partial or complete deletion of the gene have been identified. The incidence of katG mutations differs between geographical regions but represents at least 30% and up to 95% of INH-resistant clinical isolates.
The most frequent katG mutation is at codon S315, where each base (AGC) can be mutated to produce a Thr, Asn, Arg, Ile, Gly, or Leu residue. The S315T mutation can be found in up to 94% of the INH-resistant clinical isolates (81) . Two independent biochemical analyses reported that KatG(S315T) has catalaseperoxidase activities, yet its ability to oxidize INH was significantly reduced (82, 83) . Biochemical analyses of other KatG mutants showed a wide range of catalaseperoxidase and INH oxidase activities (Table 4) . Nevertheless, there is a link between INH oxidase activity and INH resistance. M. tuberculosis strains with KatG proteins deficient in INH oxidase activity were highly resistant to INH, while katG mutants with INH oxidase activity close to wild-type levels had only 2-to 4-fold increases in the MIC for INH. However, the level of INH resistance might not be defined by location of a mutation: S315T, W341G, G494D, and R595STOP variants are highly resistant to INH (84), while L141F, E553K, and F658V variants are associated with low-level INH resistance (84) . A very common polymorphism, R463L, is often found associated with other katG mutations and is more likely to be present in INH-sensitive strains than in INH-resistant strains (85) .
The high-level resistance to INH associated with katG (S315T) (MIC >1 mg/liter) was reported to be specific to the Ser→Thr amino acid change (59, 86). Brossier and colleagues found katG(S315N) only in low-level INHresistant clinical isolates (62) . Curiously, KatG(S315N) had been shown to prevent the formation of the INH-NAD adduct, suggesting that INH cannot be activated by KatG(S315N), which conflicts with the above mentioned results (87) . In a different study, a clinical isolate carrying katG (S315N) and inhA(c-15t) , which is associated with low-level resistance to INH (see above), had an MIC for INH of >256 mg/liter (88). This was the same level of resistance found in clinical isolates where katG was missing or the mutation resulted in early termination of the protein (Q434STOP) (88) . Furthermore, the INH-resistant clinical isolate containing only the inhA promoter mutation had an MIC of 0.19 mg/liter, confirming the low-level INH resistance associated with this mutation. This suggests that katG(S315N) might be associated with a high level of INH resistance in clinical isolates.
One of the first studies on the isolation of INH-resistant M. tuberculosis mutants in vitro found that the mutants could be classified into catalase-negative and highly INH-resistant or catalase-positive and weakly INHresistant (MIC <10 mg/liter) (89). Catalase-negative mutants were unable to grow in guinea pigs and rabbits, while catalase-positive mutants grew relatively well in vivo (90) . The relationship between catalase activity and fitness of an INH-resistant strain in vivo has been investigated. Pym and colleagues demonstrated that the INH-resistant M. tuberculosis KatG(T275P) variant had no detectable catalase peroxidase activity and was highly attenuated in a mouse model of infection, while M. tuberculosis carrying the KatG(S315T) variant was found to be fully virulent in mice, to have no bacterial fitness cost, and to be fully transmissible (91) . Consequently, the S315T variant is more often found in MDR-TB patients than in INH mono-resistant clinical isolates (86) and might be related to the higher transmission capabilities of this particular strain (92) . A recent study of TB patients showed that those infected with non-katG INH-resistant strains (such as inhA[c-15t]) were more likely to exhibit sputum conversion after 1 month than those infected with katG mutant strains (93) . Transmissibility, virulence, and response to chemotherapy seem to be affected by katG mutations.
Alterations of katG expression
katG is cotranscribed with its negative regulator furA (Rv1909c), a gene encoding a ferric uptake regulation protein (94, 95) . Deletion of furA in M. tuberculosis results in overexpression of katG and hypersusceptibility to INH (94) . Mutations have been identified in furA as well as in the 38-bp region between furA and katG (163) Y229F (164) K414N (165) a17 ins (139) V230A (153) R418Q (166) c30 del (160) P232R,S (139, 167) D419A,Y,E, H (59, 139) T11A (160) G234E (102) R (153) M420T (167) T12P (160) N236T (153) A424E V (163) S17N (163) A243S (163) G428R (168) G19D (163) A245V* (146) P429S (163) a98ins (160) R249C (159) c1297 ins, c1305 del (167) N35D (160) T251M (92) Q434stop (88) g109del (160) F252L (84) t1311 ins (139) W38stop (66) R254L (139) W438R (88) L48Q (146) M257I,T (143, 146) a1329 ins (139) a149 del (102) N258S (163) c1339 del (139) A61T (160) E261Q (142) L449F (169) c185 ins (160) T262R (84, 141) S457I (165) D63E (88, 141) A264T,V* (152, 163) K459STOP (168) A65T (163) H270Q (170 (92) E289D (153) N493H (142) Q88R (157) A291P,V (152, 174) G494D (59) W90R (139) STOP (88, 135, 163) L293V (139) R496L (168) W91R (88) Q295K,P,STOP (130, 146, 157) P501A (157) D94A (84) M296V (145) W505S (175), R (163) G96C (153) Q297V (146) D511del (84) H97R (139) G299S (139) (139) A312G,V (152) E553K (59) A110V (59, 84) S315T,N,I,R,G,L (59, 66, 84, 88, 135, 139, (141) (142) (143) (144) 157) c1667del (66) D117A (143) G316D, S* (66) F567S (84) G120del (84) I317L (153) D573N (92) G121C (92) V (157) E318G,V (152, 180) A574V (84) E (66) A122del (84) W321G (66) R (153) L587I,M,P* (66, 84) G123E (167) T322A,I (136, 179) P589T (163) g371 del (167) T324A,P (146, 179) G593D (84) G125C (153) T326D (181) R595stop (59) H125 ins (171) K327I (178) E607K (92) (84) K345T (92) F658V (59) K143T (92) P347L* (152) L662R (139) A144V (139) A350S,T (84, 141) G685R (135) R146W (93) Q352STOP (155) D695A,G (162, 172) L148A,P (84, 170) A361D (133) G699Q (102) Y155C (92) S (157) T363A (152) S700P (84, 157) ( Table 1) . To assess the role of these mutations, Ando and colleagues constructed isogenic strains containing the mutations found in the intergenic region (g-12a, a10c, g-7a) or in the furA coding sequence (A14V). katG expression in the g-12a strain (intergenic region) was only slightly lower than wild-type levels, and the A14V variant had no effect on KatG levels (96); however, the strains with the a-10c or g-7a mutation exhibited an 80% reduction in katG expression. This reduction was associated with a decrease in INH oxidase activity and a 2-to 4-fold increase in INH resistance, suggesting that the furA-katG intergenic region should be examined in low-level INH-resistant M. tuberculosis clinical strains.
Transcriptional analyses indicate that katG is also regulated by the sigma factor sigI (Rv1189) (97) . M. tuberculosis ΔsigI had decreased catalase capabilities and was more resistant to INH than wild-type M. tuberculosis in vitro and in vivo. Furthermore, overexpression of sigI increased the susceptibility of M. tuberculosis to INH by 2-fold. Mutations in sigI could therefore be another factor that modulates katG expression and induces low-level INH resistance in M. tuberculosis clinical isolates.
Compensatory mutations
The activity of INH against mycobacterial species is very specific. Other bacteria such as Escherichia coli and Salmonella typhimurium are not inhibited by a high dose of INH (500 mg/liter or higher; the MIC for M. tuberculosis is 0.05 mg/liter). Yet when E. coli and S. typhimurium have a deficient oxidative stress response regulator, encoded by oxyR, the strains become more sensitive to INH (MIC <50 mg/liter) (98) . M. tuberculosis oxyR′ is nonfunctional, because the coding region contains multiple frameshifts and deletions. Downstream of oxyR′ is ahpC (Rv2428), which encodes an alkyl hydroperoxide reductase. Up to 29% of INH-resistant clinical isolates contain mutations in the oxyR′-ahpC region (99) . Mutations in the oxyR′-ahpC intergenic region such as g-9a and c-15t have been shown to increase the expression of ahpC by 9-and 18-fold, respectively (100). This increase in ahpC expression is thought to compensate for the loss of KatG activity occurring in INH-resistant strains, which would render the strains more susceptible to hydrogen and organic peroxides (101) and to prevent further oxidative damage. However, most variant KatG enzymes, and in particular, KatG (S315T), are competent catalaseperoxidases, meaning that the organism is not deficient in its ability to detoxify peroxides or other compounds. With the present knowledge, the role of ahpC in INH resistance is a matter of debate. Baker et al. reported that mutations in the oxyR′-ahpC region did not contribute to INH resistance since these mutations could be found Catalase  peroxidase   A110V, A139P,  A245V, S315N,  S315T, R463L,  L587M, L619P,  L634F, D735A   L48Q  L141F,  T275P,  Q295P,  G297V,  T324P,  L587P  INH oxidase L48Q, A110V,  A245V, R463L   A139P, Q127E,  N133T, L141F,  P232S, Q295P,  G297V, T324P,  S383P, D387H,  D419H, M420T,  R489S, L634F,  D735A M176T, S315 (N,R,T), D542H, L619P, R632C (153) L378P (133) A714P (84) M176I,T (153, 167) A379T (142) V (133) A716P (141) T180C (84) K (66) T380I (153) Q717P (66) G186V,H (153) D381G (141) V725A (146) W191R, STOP (102, 172) S383P (167) A726T (139) g572 del (153) L384R (92) A727D (159) WE191-192 del (167) D387H (167) W728C (92) E195K (61) P388L,S (152) D735 del (92) W198stop (84) T390I (153) D735A (66, 84) , N (92) K200E (139) 
Detoxification of INH
In humans, INH is acetylated by the arylamine Nacetyltransferase NAT2. The rate of this detoxification reaction varies between individuals, leading to the classification of TB patients as rapid or slow inactivators depending on their NAT activity. An enzyme similar to NAT is expressed in M. tuberculosis (103 
Genes induced upon INH treatment
When M. tuberculosis comes in contact with INH, numerous genes are upregulated, as first evidenced using a method that employed differential expression using customized amplification libraries (DECAL) (106) . The availability of the M. tuberculosis genome sequence (107) led to the development of microarrays that have been used to explore the response of M. tuberculosis to INH and other drug treatments (108) . Transcriptional analysis of INH-treated M. tuberculosis revealed that M. tuberculosis upregulated a set of genes encoding proteins involved in fatty acid biosynthesis (fabD, acpM, kasA, kasB, accD6; Rv2243-2247), trehalose dimycolyl transfer (fbpC, Rv0129c), fatty acid degradation (fadE23, fadE24; Rv3139-3140), peroxidase activity (ahpC), transport (iniB, iniA; Rv0341-0342), efflux pump (efpA, Rv2846c), and unknown functions (Rv1592c, Rv1772) (106, 108 KasA is a beta-ketoacyl-ACP synthase that condenses an elongating fatty acyl-ACP with malonyl-ACP and is the first enzyme in the FASII system. KasA was once considered a more likely target of INH than InhA based on the fact that INH treatment of M. tuberculosis resulted in the inhibition of mycolic acid biosynthesis and accumulation of the long-chain fatty acid hexacosanoic acid. The accumulation of fatty acids correlated better with the inhibition of a beta-ketoacyl-ACP synthase (KasA) than with the inhibition of an enoyl-ACP reductase (InhA), which should result in the accumulation of enoyl products (unsaturated fatty acids) (109) . This biochemical red herring, however, did not consider the work of Takayama and coworkers, who demonstrated that a short exposure (5 min (109) . The authors thus concluded that KasA was the main target of INH. This conclusion was disproved by the demonstration that the complex between KasA, INH, and AcpM was formed only when InhA was inhibited (110) and by the discovery of the KasA variants D66N, G269S, and G312S in INH-sensitive strains (66) . Other kasA mutations have been identified in INH-resistant M. tuberculosis clinical isolates; however, these mutations are usually associated with katG mutations.
The INH-inducible gene iniA was shown to confer tolerance to INH when overexpressed in M. bovis BCG but not in M. tuberculosis, while deletion of iniA rendered M. tuberculosis more susceptible to INH (111) . iniA is in an operon with the INH-inducible genes iniB and iniC. Immediately upstream of this operon is Rv0340, which is transcribed in the same direction. This operon is induced specifically by drugs inhibiting mycobacterial cell wall biosynthesis such as INH and ethambutol (112) . The iniBAC operon encodes a membrane transporter, but it was shown not to transport INH (111) . All the mutations in this cluster (Table 1) were only present in INH-resistant clinical isolates; however, they were always associated with mutations in katG and/or inhA. (113) .
The finding that the NADPH-dependent β-ketoacyl-ACP reductase FabG (Rv1483), part of the FASII system, was inhibited in vitro by an INH-NADP adduct similarly to InhA (114) led others to investigate whether additional enzymes could be inhibited by this INH-NADP adduct. The enzymatic activity of the M. tuberculosis dihydrofolate reductase DHFR (Rv2763c), the target of the broad-spectrum antibiotic trimethoprim, was shown to be inhibited by the 4R-INH-NADP adduct with subnanomolar affinity (115 
Overexpression of efflux pumps
Active export of drugs from cells by efflux pumps was first described in E. coli for tetracycline (119) . In mycobacteria, low-level resistance to tetracycline and other aminoglycosides has been attributed to efflux pumps (120, 121) . iniA, a gene induced by INH treatment (106) , was shown to be a component of an MDRlike efflux pump. Overexpression of iniA conferred tolerance to INH, while deletion of iniA increased the susceptibility of mycobacteria to INH (111) . However, IniA does not pump INH out of the cells.
A microarray study of M. tuberculosis clinical isolates resistant to INH, RIF, SM, ethambutol, and ofloxacin revealed that upon INH treatment, expression of several predicted efflux pump genes was upregulated: Rv1819c, Rv2459, Rv2846, Rv3065, and Rv3728 (122). Furthermore, administration of an efflux pump inhibitor decreased the MIC for INH in these strains by at least 4-fold, suggesting that these efflux pumps may play a role in drug resistance in M. tuberculosis.
Rv1217c-1218c, an operon encoding an ATP binding cassette transporter, was shown by RT-qPCR to be overexpressed in MDR-and XDR-TB strains; the overexpression of Rv1218C was associated with increased INH resistance (123) . However, deletion of Rv1218c did not affect the MIC of INH in M. tuberculosis (124), nor did deletion of other efflux pumps such as Rv1877, mmr, and mmpL7 (125, 126) , although overexpression of mmpL7 conferred resistance to INH (127) . Conversely, deletion of lfrA led to a 2-fold decrease in the INH MIC (126) . Unexpectedly, deletion of efpA, which encodes an efflux pump that is specifically induced upon INH treatment of M. tuberculosis, resulted in increased resistance to INH and RIF in M. smegmatis (126) .
In light of these studies, the role of efflux pumps in INH resistance in M. tuberculosis needs to be further evaluated in order to assess their importance in the resistance mechanisms.
Mechanisms of Resistance to ETH Only
Alterations of EthA, the activator of ETH The mechanisms of resistance to ETH are mutations in genes encoding its activator (ethA), its target (inhA), or the ethA regulator (ethR). So far, 85 ethA mutations have been identified, although some were also found in drug-susceptible or partially ETH-resistant M. tuberculosis strains (Table 2) . Mutations have been identified throughout the length of the coding region. Approximately two-thirds of the nucleotide changes are missense mutations that result in amino acid changes, while the remaining mutations are insertions, deletions, or nonsense mutations. Unlike the katG(S315T) variant, which can be present in up to 94% of the INH-resistant clinical isolates, no dominant ethA mutation occurs in ETHresistant clinical isolates. Morlock and colleagues (61) hypothesized that the lack of cluster or dominant ethA mutations in ETH-resistant clinical isolates could be attributed to the presence of numerous monooxygenase homologs in M. tuberculosis that could protect the cells against a loss of EthA activity.
In a study by Brossier and colleagues (62), 47 ETHresistant clinical isolates were analyzed for mutations in ethA, ethR, inhA, ndh, or mshA. Of these, 22 clinical isolates (47%) had mutations in ethA, while 29 strains (62%) had a mutation in inhA (promoter region/gene). On average, the proportion of inhA mutations in ETH-resistant clinical isolates is 68%, suggesting that this is the main mechanism of ETH resistance in M. tuberculosis.
Mutations in ethR, the regulator of ethA ethA is negatively regulated by EthR (Rv3855), a transcriptional repressor belonging to the TetR family. The two genes are oriented opposite to each other, separated by a 73-bp intergenic region that contains the ethA promoter and to which EthR binds. A strain with a transposon insertion in ethR was highly sensitive to ETH, while ethR overexpression increased the resistance to ETH (45) . Two mutations in ethR have been identified (Table 2) in highly ETH-resistant clinical strains, which represent 4% of ETH-resistant clinical strains screened; however, these two strains also contained the c-15t mutation in the promoter region of inhA, and one of the two had a mutation in ethA as well (62) . Since the majority of ETH-resistant clinical isolates have mutations in ethA and/or inhA, ethR might only play a minor role in ETH resistance in M. tuberculosis clinical isolates.
CONCLUSIONS AND THE FUTURE
The mechanisms of resistance to INH and ETH in M. tuberculosis are both simple and complex (Fig. 3) . The main mechanisms of resistance are mutations in katG and ethA, the activators of INH and ETH, respectively, preventing the formation of the INH-NAD or ETH-NAD adduct, and mutations in inhA, the target of INH and ETH, leading to titration of the drug or reduced binding of the INH-NAD or ETH-NAD adduct to InhA. Numerous mutations in multiple genes have been identified in INH-or ETH-resistant M. tuberculosis clinical isolates (Tables 1 to 3 ). Ultimately, the validation of a mutation responsible for INH or ETH resistance requires transferring the point mutation into wildtype M. tuberculosis and measuring the level of resistance. This is far beyond the scope of most studies that describe mutations associated with drug resistance in M. tuberculosis.
It is often reported that a certain percentage (up to 30%) of INH-resistant M. tuberculosis clinical isolates have no mutation in any of the genes studied, leading some to conclude that there is still much more to discover about INH and ETH mode of action and resistance. Yet most studies sequenced only a small fraction of the genes known to confer INH resistance such as katG and inhA, looking only at the region around codon 315 of katG or the regulatory region of inhA. However, more than 300 mutations have been identified in katG from amino acids 1 to 735 (Table 3) , and mutations outside of the S315 region have also been shown to be highly defective in INH activation. Sequencing only a fraction of the katG gene around the S315 region might leave mutations responsible for the drug resistance phenotype undiscovered. Nevertheless, in studies where the katG and inhA genes and their regulatory regions are entirely sequenced, the mechanism of resistance is not identified in up to 5% of the INH-resistant clinical isolates.
Additional mechanisms of resistance likely remain to be identified, and a worthwhile endeavor may be to revisit the early studies on INH mechanisms of action to determine other factors of INH and ETH resistance in M. tuberculosis. Knowledge of resistance genes and mutations has provided the means to develop GenoType MTBDRplus, a rapid nucleic acid-based test for assessing INH and RIF resistance (128 
